Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma

Rationally designed combinations of targeted therapies for refractory cancers, such as activated B cell–like diffuse large B cell lymphoma (ABC DLBCL), are likely required to achieve potent, durable responses. Here, we used a pharmacoproteomics approach to map the interactome of a tumor-enriched iso...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Invest
Egile Nagusiak: Goldstein, Rebecca L., Yang, Shao Ning, Taldone, Tony, Chang, Betty, Gerecitano, John, Elenitoba-Johnson, Kojo, Shaknovich, Rita, Tam, Wayne, Leonard, John P., Chiosis, Gabriela, Cerchietti, Leandro, Melnick, Ari
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4665772/
https://ncbi.nlm.nih.gov/pubmed/26529251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI80714
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak